Plasma testosterone and arrhythmic events in male patients with arrhythmogenic right ventricular cardiomyopathy

ConclusionsThe levels of plasma testosterone in ARVC male patients are higher than those in healthy males. Testosterone level, without relation to the baseline cardiac function and future significant structural progression events, is a strong predictor of future adverse arrhythmic events in male patients with ARVC. Therefore, our results suggest that testosterone may be a useful biomarker in arrhythmic risk prediction in the ARVC.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research